2
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms
15
Papillomavirus Infections
9
Uterine Cervical Neoplasms
7
Pancreatic Neoplasms
6
Breast Neoplasms
6
Ovarian Neoplasms
5
Prostatic Neoplasms
4
Neuroendocrine Tumors
4
Neoplasm Metastasis
4
Myasthenia Gravis
3
Multiple Myeloma
3
Melanoma
3
Lymphoma
3
Lung Neoplasms
3
Autoimmune Diseases
3
Thyroid Diseases
2
Pancreatic Cyst
2
Neuroblastoma
2
Mesothelioma, Malignant
2
Lymphoma, Non-Hodgkin
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, Hairy Cell
2
Leukemia
2
Hematologic Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
COVID-19
2
Brain Neoplasms
2
Abortion, Spontaneous
2
Interventions
pembrolizumab
4
Pemetrexed
4
Carboplatin
4
Gemcitabine
3
Bevacizumab
3
tusamitamab ravtansine
2
Vinorelbine
2
Ramucirumab
2
Erlotinib Hydrochloride
2
Docetaxel
2
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
2
vistusertib
1
vandetanib
1
telomerase reverse transcriptase p572Y, human
1
spartalizumab
1
sotorasib
1
sintilimab
1
olaparib
1
necitumumab
1
icotinib
1
durvalumab
1
dacomitinib
1
capivasertib
1
aumolertinib
1
Radiosurgery
1
Platinum
1
Paclitaxel
1
MLN 8237
1
LY3023414
1
Injections
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Non-small Cell Lung Cancer Metastatic
×
Data Collection
×
Clear all
NCT04994795
2024-11-21
DEEP-Lung-IV
Sophia Genetics SAS
Active not recruiting
4,000 enrolled